EP1746097A1 — 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
Assigned to Aventis Pharma SA · Expires 2007-01-24 · 19y expired
What this patent protects
1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them. The outstanding invention is about substituted dihydropyridine-fused heterocycles useful for the treatment of cancer disease, especially for preventing cancerous cells to…
USPTO Abstract
1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them. The outstanding invention is about substituted dihydropyridine-fused heterocycles useful for the treatment of cancer disease, especially for preventing cancerous cells to divide. These compounds act as inhibitors of Aurora A and/or B kinases.
Drugs covered by this patent
- Scemblix (ASCIMINIB HYDROCHLORIDE) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.